Fulcrum Therapeutics, Inc.FULCNASDAQ
Loading
SG&A Expenses Over TimeContracting
Percentile Rank50
3Y CAGR-11.7%
5Y CAGR+6.0%
Year-over-Year Change
Selling, general, and administrative expenses
3Y CAGR
-11.7%/yr
vs +49.6%/yr prior
5Y CAGR
+6.0%/yr
Recent deceleration
Acceleration
-61.4pp
Decelerating
Percentile
P50
Within normal range
vs 5Y Ago
1.3x
Solid growth
Streak
3 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $28.67M | -21.4% |
| 2024 | $36.45M | -12.5% |
| 2023 | $41.67M | -0.1% |
| 2022 | $41.69M | +36.6% |
| 2021 | $30.52M | +42.7% |
| 2020 | $21.39M | +62.7% |
| 2019 | $13.14M | +58.1% |
| 2018 | $8.31M | +84.8% |
| 2017 | $4.50M | - |